# Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia

> **NCT02240173** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Federal Neuro-Psychiatric Hospital, Yaba** · enrollment: 100 (estimated)

## Conditions studied

- Schizophrenia and Disorders With Psychotic Features

## Interventions

- **DIETARY_SUPPLEMENT:** Jobelyn
- **DRUG:** Haloperidol

## Key facts

- **NCT ID:** NCT02240173
- **Lead sponsor:** Federal Neuro-Psychiatric Hospital, Yaba
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-06
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2017-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02240173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02240173, "Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT02240173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*